SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Sharp Chula Vista Medical Center announced plans Monday to build a $239 million hospital called Ocean View Tower in South County.
Medical device maker ResMed Inc. announced Monday that it has acquired Maribo Medico, a Denmark-based company specializing in sleep-disordered breathing medical devices.
Pfenex Inc., a clinical-stage biotechnology company developing biosimilar therapeutics, reported third quarter financial earnings.
Epic Sciences Inc., a diagnostic company focused on the analysis of circulating tumor cells in the blood, announced that it’s collaborating with the Abramson Cancer Center of the University of Pennsylvania on multiple studies to help improve personalized therapies for cancer treatment.
The National Institute on Aging awarded NeuroGenetic Pharmaceuticals Inc. a biopharmaceutical company focused on Alzheimer’s disease therapeutics, $2.5 million grant for its first human clinical trials on a molecule that could treat and prevent Alzheimer’s disease.
The ongoing contract impasse between Tri-City Medical Center and the SEIU-United Healthcare Workers West could lead to a first for San Diego County: A ballot initiative on executive pay.
Faheem Hasnain, a well-respected biotech executive in San Diego, has left his post as chief executive officer of Receptos Inc.
Neothetics Inc., a maker of cosmetic pharmaceutical therapies, reported earnings for the third quarter of 2015.
San Diego-based Amplyx Pharmaceuticals announced Wednesday that the company has closed on a $40.5 million Series B financing.
DJO Global Inc., a medical device company in Vista, announced its third-quarter financial results and its plan to exit the Empi business.
BioDuro, LLC, a life sciences research organization, has merged its U.S. operations with Formex, LLC, a drug development and manufacturing company. Both are headquartered in San Diego.
La Jolla-based Sophiris Bio Inc. announced Tuesday that its sole drug in development met the main goal of a late-stage study. The results have revived hopes for market approval nearly a year after the company's interim analysis suggested the treatment would fail the study.
Nearly two-thirds of registered nurses over 54 are now considering retirement, according to AMN Healthcare and its Center for the Advancement of Healthcare Professionals.
Isis Pharmaceuticals Inc. announced financial results for the third quarter of this fiscal year.
San Diego’s HUYA Bioscience International announced Monday a strategic collaboration with TechCode Gu'an Life Sciences Park near Beijing.